MedTrace Logo

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

NCT01144754 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-07-01

No results posted yet for this study

Summary

This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made during normal clinical practice.

Conditions

Interventions

DRUG

Rituximab

Calculated per patient

Sponsors & Collaborators

Principal Investigators

  • Kristen N. Ganjoo · Stanford University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144754 on ClinicalTrials.gov